How Cysts Form

The Genetic Basis of ADPKD

ADPKD is caused by mutations in the PKD1 gene (approximately 85% of patients) or the PKD2 gene (approximately 15% of patients). PKD1 is located on the short arm of chromosome 16 and encodes polycystin-1 (PC1); PKD2 is located on the long arm of chromosome 4 and encodes polycystin-2 (PC2).

The inheritance pattern is autosomal dominant: each child of an affected parent has a 50% chance of inheriting the disease-causing gene. Males and females are affected equally. PKD1 mutation patients typically have earlier onset and faster progression than PKD2 mutation patients, but individual variation is large.

Polycystins: Signal Sensors on the Cell Surface

Structure of PC1 and PC2

PC1 is a large transmembrane protein (approximately 4,300 amino acids) with a long extracellular domain that can sense extracellular mechanical and chemical signals. PC2 is a smaller transmembrane protein (approximately 968 amino acids) belonging to the transient receptor potential (TRP) channel family, forming a calcium ion channel.

Recent structural biology studies reveal that PC1 and PC2 form a heteromeric complex composed of 1 PC1 molecule and 3 PC2 molecules. Interestingly, PC2 can also independently form homomeric calcium channels in the primary cilium, mediating calcium influx on its own.

The Primary Cilium: Where Polycystins Work

Each kidney tubule epithelial cell has a single, slender primary cilium extending from its apical surface into the tubular lumen. The primary cilium was long overlooked until its defects were found to cause polycystic kidney disease, revealing it as an important mechanosensory organelle.

When urine flows through the tubular lumen, fluid shear force bends the primary cilium. The PC1-PC2 complex senses this mechanical signal, opening the PC2 calcium channel, allowing calcium ions to flow from the cilium into the cell, triggering a cascade of intracellular calcium signaling. This mechanism allows tubule cells to "sense" urine flow in the lumen and regulate cell behavior accordingly.

Key point: Loss of polycystin function prevents cells from properly sensing fluid signals, triggering abnormal cell proliferation and fluid secretion — this is the starting point of cyst formation.

The Two-Hit Hypothesis: Why Cysts Appear Gradually

ADPKD is autosomal dominant, but patients' kidneys are usually normal or have only a few small cysts at birth. Cysts appear and enlarge gradually over decades. Why don't all tubule cells form cysts simultaneously?

The answer lies in the two-hit hypothesis:

1. First hit (germline mutation): The patient inherits one mutated PKD1 or PKD2 allele from a parent. At this point, each tubule cell has one mutated copy and one normal copy.
2. Second hit (somatic mutation): During life, the normal allele in individual tubule cells is inactivated by random mutation, oxidative damage, or other causes. That cell now has both copies nonfunctional, completely losing polycystin function.
3. Clonal expansion: The cell that lost polycystin function begins to proliferate abnormally, forming a cyst. Each cyst arises from the clonal expansion of a single cell.

This explains why cysts appear gradually — the second hit is a random event that accumulates over time. It also explains why disease severity varies greatly among patients in the same family — the frequency and location of somatic mutations differ.

Molecular Consequences of Polycystin Loss of Function

Decreased Intracellular Calcium

Normally, the PC2 channel maintains basal calcium levels in the primary cilium and cytoplasm. After polycystin loss of function, intracellular calcium concentration decreases. Calcium is a regulator of many signaling pathways, and reduced calcium alters how cells respond to multiple signals.

cAMP Signaling Reversal

This is one of the most central pathogenic mechanisms in ADPKD. In normal kidney tubule cells, cAMP typically inhibits cell proliferation. But in PKD cells, due to reduced intracellular calcium, cAMP's effect is reversed — it instead promotes cell proliferation by activating the B-Raf → MEK → ERK pathway.

Meanwhile, cAMP activates PKA, which phosphorylates and opens the CFTR chloride channel; chloride ions are secreted into the cyst lumen, sodium follows, and water enters the lumen by osmosis — this drives fluid secretion and cyst expansion.

The Central Role of the Vasopressin V2 Receptor

The vasopressin V2 receptor (V2R) on the surface of collecting duct principal cells is the main driver of cAMP production. When vasopressin (antidiuretic hormone) binds V2R, it activates adenylyl cyclase 6 (AC6) via the Gs protein, generating large amounts of cAMP.

In PKD, this normal physiological signal becomes a pathological one — V2R-driven cAMP production both promotes cyst epithelial proliferation and drives fluid secretion. This is why:

• Tolvaptan (a V2R antagonist) can effectively slow cyst growth — it blocks the main source of cAMP.
• Adequate hydration is theoretically beneficial — lowering plasma osmolality reduces vasopressin secretion, thereby reducing V2R activation.
• Elevated copeptin (a fragment of the vasopressin precursor, used as a surrogate marker for vasopressin levels) predicts faster disease progression.

mTOR Pathway Activation

Polycystin loss of function also activates the mammalian target of rapamycin (mTOR) pathway, promoting cell growth and protein synthesis. mTOR is normally regulated by energy and nutrient status in healthy cells, but in PKD cells it is aberrantly activated, promoting cyst epithelial enlargement and proliferation.

However, mTOR inhibitors (everolimus, sirolimus) in human clinical trials slowed kidney volume growth but failed to slow kidney function decline, failing to translate structural benefit into functional benefit. This suggests that the mTOR pathway is only one participant in cyst growth, and blocking it alone is insufficient to alter disease course.

Metabolic Reprogramming: "Tumor-Like" Behavior of Cyst Cells

Recent research has found that ADPKD cyst cells undergo tumor-like metabolic reprogramming, known as the "Warburg effect":

• Enhanced aerobic glycolysis: Even under aerobic conditions, cyst cells preferentially generate energy through glycolysis, producing large amounts of lactate.
• Suppressed fatty acid oxidation: Mitochondrial fatty acid oxidation capacity is reduced.
• Mitochondrial dysfunction: Oxidative phosphorylation capacity is reduced, and ATP production patterns are altered.

This metabolic shift is driven by mTORC1, HIF-1α, c-MYC, and other factors. 13C-glucose isotope tracing studies in human PKD1 kidney tissue confirmed enhanced glycolytic flux. Metabolic reprogramming provides a theoretical basis for dietary interventions (e.g., carbohydrate restriction, ketogenic diet) and novel drug targets (e.g., GLP-1 receptor agonists) in ADPKD, but most of these remain in preclinical or early clinical trial stages.

From a Single Cell to a Visible Cyst

A tubule cell that has undergone the second hit goes through the following process to form a visible cyst:

1. Abnormal proliferation: cAMP-ERK and mTOR pathways drive cell division, increasing cell number.
2. Fluid secretion: CFTR chloride channels and Na-K-ATPase drive fluid secretion into the intercellular lumen, forming a cyst cavity.
3. Disconnection from the tubule lumen: As the cyst enlarges, it disconnects from the original tubular lumen, becoming an independent closed cavity.
4. Continuous expansion: The cyst wall epithelium continues to proliferate and secrete fluid, and the cyst gradually enlarges.
5. Compression of surrounding tissue: The enlarging cyst compresses surrounding normal tubules and blood vessels, causing ischemia and fibrosis.

Why Not All Nephrons Form Cysts

Although all of the patient's cells carry the germline PKD1/PKD2 mutation, only a few cells undergo the second hit to form cysts. It is estimated that even in end-stage polycystic kidneys, only about 1–5% of nephrons have formed cysts. Factors influencing the frequency of second hits include:

• Genotype: PKD1 truncating mutations progress faster than missense mutations.
• Somatic mutation rate: Oxidative stress, inflammation, and nephrotoxins may increase somatic mutation frequency.
• Cellular microenvironment: Different tubular segments have different proliferative capacities and signaling environments.
• Epigenetic factors: Changes in gene expression regulation may influence disease manifestation.

Practical Significance of Understanding the Mechanism

Understanding the cyst formation mechanism helps you understand why existing treatments are designed the way they are:

• Tolvaptan targets the V2R-cAMP pathway — currently the only drug proven to slow ADPKD progression.
• Blood pressure control with ACEI/ARB — reduces the additional injury to remaining nephrons from RAAS activation and glomerular hypertension.
• Adequate hydration — reduces vasopressin secretion and V2R activation (but clinical trials show that simply drinking more water cannot replace tolvaptan).
• Sodium restriction — high sodium intake is associated with faster cyst growth; sodium restriction may slow progression.
• Avoiding nephrotoxins — reduces oxidative damage that may increase the frequency of second hits.

It is also important to understand that targeted therapies for many mechanisms (such as metabolic reprogramming, autophagy, mTOR) are still under investigation and should not be attempted without medical guidance.

← Back to Knowledge Base